Lipoic acid: Difference between revisions

According to the [[American Cancer Society]] as of 2013, "there is no reliable scientific evidence at this time that lipoic acid prevents the development or spread of cancer".<ref>{{cite web|url=http://www.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/lipoic-acid|title=Lipoic Acid|date=November 2008|publisher=[[American Cancer Society]]|access-date=5 October 2013}}</ref> As of 2015, intravenously administered ALA is unapproved anywhere in the world except Germany for [[diabetic neuropathy]], but has been proven reasonably safe and effective in four clinical trials; however another large trial over four years found no difference from placebo.<ref>{{cite journal|last1=Javed|first1=S|last2=Petropoulos|first2=IN|last3=Alam|first3=U|last4=Malik|first4=RA|title=Treatment of painful diabetic neuropathy.|journal=Therapeutic Advances in Chronic Disease|date=January 2015|volume=6|issue=1|pages=15–28|pmid=25553239|pmc=4269610|doi=10.1177/2040622314552071}}</ref> As of 2012, there was no good evidence alpha lipoic acid helps people with [[mitochondrial disorders]].<ref name="pmid22513923">{{cite journal | vauthors = Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF | title = Treatment for mitochondrial disorders | journal = Cochrane Database Syst Rev | issue = 4 | pages = CD004426 | date = April 2012 | volume = 2012 | pmid = 22513923 | doi = 10.1002/14651858.CD004426.pub3 | pmc = 7201312 }}</ref> A 2018 review recommended ALA as an anti-obesity supplement with low dosage (< 600&nbsp;mg/day) for a short period of time (<10 weeks); however, it is too expensive to be practical as a complementary therapy for obesity.<ref name="Namazi">{{cite journal | last1=Namazi | first1=Nazli | last2=Larijani | first2=Bagher | last3=Azadbakht | first3=Leila | title=Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials | journal=Clinical Nutrition| volume=37 | issue=2 | year=2018 | issn=0261-5614 | doi=10.1016/j.clnu.2017.06.002 | pages=419–428|pmid=28629898}}</ref>